Mammoth Biosciences CRISPR Dystrophin Editing Patent Application
Summary
USPTO published patent application US20260097134A1 assigned to Mammoth Biosciences, Inc. covering CRISPR-Cas systems and methods for editing human dystrophin genes to treat Duchenne muscular dystrophy (DMD). The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids for gene modification therapies.
What changed
USPTO published patent application US20260097134A1 from Mammoth Biosciences covering systems, compositions, and methods for modifying the human dystrophin gene using CRISPR-Cas technology for Duchenne muscular dystrophy treatment. The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids.
This patent application represents potential intellectual property protection for gene editing approaches targeting DMD. Parties conducting gene editing research or developing DMD treatments should monitor this application for potential freedom-to-operate implications.
What to do next
- Monitor for updates
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR PRECISE EDITING OF HUMAN DYSTROPHIN
Application US20260097134A1 Kind: A1 Apr 09, 2026
Assignee
Mammoth Biosciences, Inc.
Inventors
Yuchen GAO, Ning CHAI, Wiputra Jaya HARTONO, Benjamin Julius RAUCH, Aaron DELOUGHERY, Stepan TYMOSHENKO, William Douglass WRIGHT, Paula GONCALVES CERQUEIRA, Brian R. CHAIKIND, Kevin Cristopher WILKINS
Abstract
Disclosed herein are systems, compositions, and methods for modifying the human dystrophin gene (DMD). Systems, compositions, and methods may comprise a compact Type V CRISPR-associated (Cas) protein, an RNA-dependent DNA polymerase, and/or one or more guide nucleic acids or uses thereof. These systems, compositions, and methods may be useful for treating diseases such as Duchenne muscular dystrophy (DMD).
CPC Classifications
A61K 48/0058 C12N 9/1276 C12N 9/224 C12N 15/11 C12N 15/86 C12N 15/907 C12Y 207/07049 C12N 2310/20 C12N 2750/14143
Filing Date
2025-12-05
Application No.
19410151
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.